Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints

Maturitas

Volumn 23, Issue 1, 1996, Pages 55-62

  Egarter, Ch ^a   Huber, J ^a   Leikermoser, R ^b   Haidbauer, R ^c   Pusch, H ^d   Fischl, F ^a   Putz, M ^e  

^a UNIVERSITY OF VIENNA   (Austria)

^b KH Elisabethinen   (Austria)

^c Menox Salzburg   (Austria)

^d UNIVERSITY OF GRAZ   (Austria)

^e Hospital SMZ Ost   (Austria)

Author keywords

Climacteric; Endometrium; Hormone replacement therapy; Tibolone

Indexed keywords

COLPRON; CONJUGATED ESTROGEN; MEDROGESTONE; TIBOLONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLIMACTERIUM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENDOMETRIUM; FEMALE; HEADACHE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSAL SYNDROME; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYMPTOMATOLOGY; ULTRASOUND; WEIGHT GAIN;

EID: 0030000556     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5122(95)00953-1     Document Type: Article

References (15)

1. Schiff I, Komarov Sela H, Cramer D, Tulchinsky D, Ryan KJ. Endometrial hyperplasia in women on cyclic or continuous estrogen regimens. Fertil Steril 1983; 37: 79-82.
2. De Visser J, Coert A, Feenstra H, Van der Vies J. Endocrinological studies with Org OD 14. Arzneim Forsch 1984; 34: 1010-1017.
3. Jelinek J, Kappen A, Schinbaum E, Lomax P. A primate model of human postmenopausal hot flushes. J Clin Endocrinol Metab 1984; 59: 1224-1228.
4. Ginsburg J, Prelevic G, Butler D, Okolo S. Clinical experience with tibolone (Livial®) over 8 years. Maturitas 1995; 21: 71-76.
5. Ross LA, Alder EM. Tibolone and climacteric symptoms. Maturitas 1995; 21: 127-136.
6. Rymer J, Chapman MG, Fogelman I. Effect of tibolone on postmenopausal bone loss. Osteoporosis Int 1994; 4: 314-319.
7. Kupperman HS, Blatt MHG, Wiesbader H., Filler W. Comparative clinical evaluation of the estrogenic preparations by the menopausal and amenorrheal indices. J Clin Endocrinol 1953; 6: 688-703.
8. Volpe A, Facchinetti F, Grasso A, Petraglia F, Campanini D, Genazzani AR. Benefits and risks of different hormonal replacement therapies in postmenopausal women. Maturitas 1986; 8: 327-334.
9. Crona N, Samsioe G, Lindberg UB, Slilferstolpe G. Treatment of climacteric complaints with Org OD 14: a comparative study with oestradiol valerate and placebo. Maturitas 1988; 9: 303-308.
10. Tax L. Goorissen EM, Kicovic PM. Clinical profile of Org OD 14. Maturitas 1987; Suppl. 1: 3-13.
11. Genazzani AR, Petraglia F, Facchinetti AD, Genazzani M, Bergamaschi A, Grasso A, Volpe A. Effects of Org OD 14 on pituitary and peripheral endorphin in castrated rats and in postmenopausal women. Maturitas 1987; Suppl. 1: 35-48.
12. Kicovic PM, Cortes-Prieto J, Milojevic S, Franchi F. Placebo-controlled cross over study of effects of Org OD 14 in menopausal women. Reproduction 1982; 6: 81-91.
13. Maguess RB, Rosenfeld CR. Local and systemic estradiol-17-β. Effects on uterine and systemic vasodilation. Am J Physiol 1989; 256: E536-E542.
14. Punnonen R, Liukko P, Cortes-Prieto J, Eydam F, Milojevic S, Trévoux R, Chryssikopoulos E, Franchi F, Luisi M, Kicovic PM. Multicentre study of effects of ORG OD 14 on endometrium vaginal cytology and cervical mucus in post-menopausal and oophorectomised women. Maturitas 1984; 5: 281-286.
15. Meuwissen JHJM, Wiegerinck MAHM, Haverkorn MJ. Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy. Maturitas 1995; 21; 121-125.